Summit Therapeutics Inc. Share Price & Technical Analysis
SMMT · $12.70 (-11.13%)
Healthcare / Biotechnology
$12.70
-11.13%
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-14% return in Jun, 16% avg return in past 3 year Jun month.
24% return in 2026, 87% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -19% | 17% | 19% | 12% | 9% | -14% | – | – | – | – | – | – | 24% |
| 25 | 19% | 1% | -7% | 26% | -25% | 13% | 24% | -8% | -10% | -9% | -4% | 0% | 18% |
| 24 | 50% | 15% | -11% | -7% | 123% | -20% | 38% | 20% | 68% | -14% | -3% | -4% | 257% |
| 23 | -19% | -49% | 0% | -28% | 14% | 56% | -16% | -24% | 19% | 0% | 0% | 30% | -15% |
| 22 | -15% | 23% | -14% | -36% | -19% | -29% | 0% | 20% | 0% | -8% | -27% | 425% | 320% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$11.21B
P/E ratio
—
52W high
$30.98
52W low
$12.65
Volume
48,78,816
Beta
-1.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Summit Therapeutics Inc. share price today?
- Summit Therapeutics Inc. (SMMT) last traded around $12.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SMMT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SMMT. Download the app for real-time alerts.
- How can I analyze Summit Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.